Ascend Wellness Preps Reverse Split Ahead of US Uplisting

Photo by Pixabay via Pexels.

Ascend Wellness Holdings just put a specific date on the calendar for a move that's been telegraphed across the multistate operator world for months. The Chicago-based cannabis company filed a definitive proxy statement with the SEC calling a special stockholder meeting to vote on a reverse stock split -- the kind of unglamorous mechanical step that usually only matters to people who read 8-Ks for fun, except this one is widely understood as the on-ramp to a US exchange uplisting.

Ascend isn't inventing this playbook. Trulieve and Glass House Brands both uplisted to the NYSE within the last couple months, and Curaleaf and Verano have already executed their own reverse splits while they wait on a bigger regulatory shoe to drop. Ascend CEO Sam Brill has framed the split not as routine housekeeping but as a response to a federal landscape that's actually moving, tying the company's timing directly to the rescheduling process working its way through Washington. Whether that optimism is fully justified is a separate question -- but the filing itself is concrete, and worth walking through.

What Ascend Just Filed With the SEC

Photo by Pavel Danilyuk via Pexels.

The paperwork is specific down to the minute. Ascend's special meeting of stockholders is set for Friday, August 28, 2026, at 11:00 a.m. Eastern, and it's being held virtually rather than in a physical boardroom -- standard practice at this point for special meetings that are really about a single up-or-down procedural vote. Proxies need to be submitted by 11:00 a.m. Eastern on Wednesday, August 26, 2026, giving shareholders a two-day buffer before the meeting itself. The record date -- the cutoff that determines who's even eligible to vote -- was set earlier, on July 7, 2026.

As of that record date, Ascend had 203,033,639 shares of Class A common stock issued and outstanding, which gives a sense of the scale of the float that would be affected by any consolidation. For the vote to count at all, the company needs a quorum: holders representing at least one-third of the total voting power have to show up (virtually) or be represented by proxy. If that threshold isn't hit, the meeting doesn't fail outright -- it simply adjourns for one week, reconvening at the same time the following Friday.

The actual mechanics of the split are where Ascend has left itself room to maneuver. Rather than committing to a fixed ratio now, the proxy proposes a range -- anywhere from 1-for-10 to 1-for-50 -- with the board authorized to pick the exact number later, timed to whatever a US exchange listing application actually requires. That flexibility matters, because the right ratio depends on where Ascend's stock is trading when the company is ready to file, not where it sits today.

Why a Reverse Split Comes Before an Uplisting

Photo by Nick Chong via Unsplash.

Reverse splits get a bad reputation in some corners of the market, often read as a sign of distress. In the cannabis context, though, they're increasingly just a technical prerequisite. The NYSE and Nasdaq both enforce minimum per-share price requirements for listed companies, and most multistate operators -- trading for years on the Canadian Securities Exchange or over-the-counter markets like the OTCQX -- have share prices that fall well under those thresholds. A reverse split doesn't change the underlying value of the company; it just consolidates existing shares into fewer, higher-priced ones, which is often the cleanest way to satisfy a listing standard without doing anything to the balance sheet.

Ascend currently trades as AAWH-U.CN on the CSE and as AAWH on the OTCQX, and the company has been careful in its filing not to oversell the outcome. There's no guarantee, Ascend notes, that a US exchange listing actually follows the split, or that the higher post-split share price holds once trading resumes. Consolidating shares can just as easily produce a stock that drifts right back down if the underlying investor demand isn't there.

Brill's public rationale leans less on the mechanics and more on what a listing would unlock: broader access to institutional capital, a wider investor base that's been unable to touch cannabis equities on compliance grounds, and opportunities that have simply been out of reach for plant-touching operators for years. His phrase about moving decisively 'as those doors open' is doing a lot of work here -- it's a direct nod to the idea that federal rescheduling is shifting what's actually possible, and that operators who move early will be better positioned than those who wait.

A DEA Filing Adds to the Momentum

Photo by Pexels via Pixabay.

The reverse split isn't the only regulatory filing Ascend has made recently, and the second one arguably matters more for the long-term thesis. On June 30, Ascend filed for DEA registration covering its state-licensed medical cannabis operations, using the expedited pathway that opened up after April's rescheduling order moved marijuana toward Schedule III. That pathway is specifically designed for existing state-licensed medical operators, letting them seek federal registration without starting from zero.

The filing applies to dispensary operations that serve medical patients across Ascend's core markets, which is a meaningful detail because it draws a clear line between Ascend's approach and the one taken by Trulieve and Glass House. Both of those companies divested their adult-use holdings to reposition as medical-only operators -- a structural simplification that presumably made their own federal filings and NYSE uplistings more straightforward.

Ascend hasn't gone that route. The company continues to operate in adult-use markets across its footprint, which spans Illinois, Maryland, Massachusetts, Michigan, New Jersey, Ohio, and Pennsylvania -- a mix of medical and adult-use licenses depending on the state. Keeping the adult-use business intact isn't necessarily disqualifying for a future federal registration or an eventual uplisting, but it does add a layer of complexity that the medical-only operators have already shed. It's a bet that the two can coexist under a reshaped federal framework, rather than a bet that they can't.

Ascend Isn't Alone: The Broader Uplisting Wave

Photo by Anne Nygård via Unsplash.

Ascend's timing only makes sense in the context of how fast this has all moved for its peers. Trulieve began trading on the NYSE under the ticker TRLV on June 10, 2026, and Glass House Brands followed just three weeks later, debuting under GLAS on June 30. Both moves came after each company had already gone through its own reverse split and, in Trulieve's and Glass House's cases, after narrowing their operations toward the medical side of the business.

Curaleaf and Verano have taken a related but distinct path. Both completed reverse stock splits in early June -- Curaleaf at a 1-for-3 ratio, Verano at 1-for-5 -- clearing the same mechanical hurdle Ascend is now working through. But neither has committed to an uplisting application yet. Both are reportedly waiting on the outcome of an administrative law judge hearing tied to the broader rescheduling proceeding before deciding how to proceed, in the hope that a favorable outcome would let them uplist without having to unwind their adult-use businesses the way Trulieve and Glass House did.

Taken together, the pattern looks less like isolated corporate decisions and more like a sector-wide repositioning. Five of the largest multistate operators are now either uplisted, mid-process, or actively preparing the paperwork, all within the space of a few months, all citing the same shifting federal backdrop. It's the clearest sign yet that MSOs see a real, finite window to access mainstream capital markets, and none of them want to be the last one still trading over-the-counter when that window narrows.

Ascend's approach -- split first, keep the door open on adult-use, file for DEA registration separately -- puts it in a middle position between the medical-only path Trulieve and Glass House already took and the wait-and-see stance Curaleaf and Verano are holding. It's a bet that a federally rescheduled cannabis industry won't force operators to choose between adult-use revenue and Wall Street access, even though the two companies furthest along in this process both made that trade.

How much any of this actually delivers depends on variables well outside Ascend's control. The pending ALJ decision on rescheduling could reshape what federal registration even requires for operators still selling recreationally, and investor reception to a 10-to-1 or 50-to-1 consolidated share price is genuinely unpredictable -- reverse splits have a way of triggering renewed selling pressure just as often as they stabilize a stock.

For now, the concrete checkpoint is August 28. If shareholders clear the reverse split, Ascend removes one mechanical obstacle to uplisting, but the harder questions -- which exchange, what ratio, and on what timeline -- stay unanswered until the company decides the regulatory ground is solid enough to file. As with most things touching federal cannabis policy right now, the paperwork is moving faster than the underlying law, and investors watching this space should treat every filing as provisional until the rescheduling process actually finishes.